Healthtech firm launches world’s first consumer epigenetic testing kit with £1.12m investment
Healthtech company Chronomics has raised seven-figure seed funding and launched the world’s first consumer epigenetic testing kit.
The company has secured over £1.12m funding to date, including significant investment from venture capital firm Anthemis and follow-on backing from SOSV.
Other investors in Chronomics include angel Laurence Garrett, senior partner at Highland Europe.
Chronomics is seeking to revolutionise attitudes towards health management. It offers an epigenetic saliva test that profiles specific lifestyle and environmental indicators and provides accurate insights into an individual’s health, including their biological age and metabolic status.
The company was founded by Dr Tom Stubbs, Daniel Herranz, Dr Toby Call and Charles Ball.
Vica Manos of Anthemis said: “Physical health and mental wellbeing are crucial pieces to the puzzle of an individual’s financial wellness.
“The team is combining a brand-new data source and cutting-edge science to help consumers make better, more informed decisions about their lifestyle, which is really exciting.”
He added: “We are delighted to support the Chronomics team as they gear up for the next phase of their journey.”
SOSV venture partner Bill Liao commented: “We have always been interested in the DNA testing space, and Chronomics is the first company that we have discovered that radically departs from the ‘once in a lifetime’ test business model, to a subscription.
“It actually shows how your epigenome changes over time, why that matters and what to do about it! What’s more, it’s in an area completely untapped in terms of consumer access.”
Angel investor Laurence Garrett said: “The Chronomics team are academically exceptional. The company has responded to an increased desire amongst people to improve the quality of their lives through sound scientific data about their epigenetic profile.
“I am grateful to Tom and the team for allowing me to become an investor in their business.”
Chronomics CEO Dr Tom Stubbs said: “Reaching £1.12m in seed funding is a momentous milestone for Chronomics, having just launched the company last year.
“Receiving the support of prominent backers reflects their confidence in our company, and our vision of a future of personalised and proactive health management.”